Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

Zest Meds is more than just a healthcare provider; it’s a partner in your weight loss journey. Specializing in cutting-edge treatments like Semaglutide and Tirzepatide, Zest Meds has positioned ...

Lilly revised its revenue guidance down 5%, to $13.5 billion, missing consensus of $14 billion by $500 million. But the guidance still represents a 45% increase from the same quarter in 2023. Lilly ...

Up to 3.4 million eligible patients could benefit from the medication that treats type 2 diabetes and aids weight loss ...

Obesity levels in the UK may have peaked and could start dropping ‘significantly’ in 2025 due to weight loss jabs, according ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

The U.S. Food and Drug Administration (FDA) recently approved Zepbound® (tirzepatide) as the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

The New Year is a time of reflection and change for many Americans, who start each January with a clean slate and goals for ...

The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for ...

Eli Lilly's experimental weight loss drug, retatrutide, has demonstrated encouraging results in helping obese adults lose weight.